A record for the reading desk
Tesamorelin
Aliases: Egrifta WR
The recorded fields, their references, and a question worth keeping.
- Status
- Approved product
- Evidence label
- Randomized evidence
- Index topics
- Hormones
- Status as of
Record / 01
Recorded fields
- Mechanism
- Stimulates growth-hormone release.
- Evidence
- A randomized trial measured visceral fat.
- Limitations
- Not for weight management.
- Safety
- Active malignancy is a contraindication.
- Route context
- Specified subcutaneous formulation.
- Approval scope
- Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
Reasoning / 02
A note for your reading
A condition can be required for a conclusion without being enough to establish it. Consider a set of entry rules: meeting a required rule removes one obstacle, but other requirements might remain. Conversely, a combination that guarantees entry need not be the only combination that does so. When reading an argument, notice whether it says must have, enough to establish, or both. Those phrases make different commitments. Translating the claim into a simple if statement helps reveal whether the reasoning has quietly turned a requirement into a guarantee.
Keep asking / 03
Three questions to carry forward
- Is this condition presented as required, sufficient, or both at once?
- What other requirements could remain after this particular condition has been met?
- Does the conclusion mistakenly treat passing a requirement as a complete guarantee?
Trace the record / 04
References
- EGRIFTA WR
NLM · Checked
- Falutz trial
PubMed · Checked